Camilla Hansen
Presidente en Aloop Therapeutics ApS .
Perfil
Camilla Petrycer Hansen is currently the Chairman at Aloop Therapeutics ApS, the Director at Hoba Therapeutics ApS, and the Director at LimmaTech Biologics AG.
She previously worked as the Principal at Novo Seeds and Novo Holdings Ltd.
Additionally, she has experience as the Director at Centauri Therapeutics Ltd.
Dr. Hansen holds a graduate and doctorate degree from the University of Copenhagen.
Cargos activos de Camilla Hansen
Empresas | Cargo | Inicio |
---|---|---|
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Inversor de Capital Privado | 01/06/2018 |
Novo Holdings Ltd.
Novo Holdings Ltd. Financial ConglomeratesFinance Part of Iron Mountain, Inc., Novo Holdings Ltd. functions as an investment holding British company. The company is based in London, UK. | Corporate Officer/Principal | - |
Hoba Therapeutics ApS
Hoba Therapeutics ApS BiotechnologyHealth Technology Hoba Therapeutics ApS engages in research and experimental development in biotechnology. The firm’s purpose is commercialization of pharmaceuticals and biotechnology services. The company was founded on November 28, 2016 and is headquartered in Copenhagen, Denmark. | Director/Miembro de la Junta | - |
Aloop Therapeutics ApS
Aloop Therapeutics ApS Pharmaceuticals: MajorHealth Technology Aloop Therapeutics ApS manufactures pharmaceutical preparations. The company is based in Copenhagen, Denmark. The CEOs are Søren Sylvester Skjærbæk, Thomas Kirkegaard Jensen. The Danish company was founded in 2022. | Presidente | - |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Director/Miembro de la Junta | 09/10/2023 |
Antiguos cargos conocidos de Camilla Hansen.
Empresas | Cargo | Fin |
---|---|---|
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Director/Miembro de la Junta | - |
Formación de Camilla Hansen.
University of Copenhagen | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 6 |
---|---|
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Finance |
Novo Holdings Ltd.
Novo Holdings Ltd. Financial ConglomeratesFinance Part of Iron Mountain, Inc., Novo Holdings Ltd. functions as an investment holding British company. The company is based in London, UK. | Finance |
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
Hoba Therapeutics ApS
Hoba Therapeutics ApS BiotechnologyHealth Technology Hoba Therapeutics ApS engages in research and experimental development in biotechnology. The firm’s purpose is commercialization of pharmaceuticals and biotechnology services. The company was founded on November 28, 2016 and is headquartered in Copenhagen, Denmark. | Health Technology |
LimmaTech Biologics AG
LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Commercial Services |
Aloop Therapeutics ApS
Aloop Therapeutics ApS Pharmaceuticals: MajorHealth Technology Aloop Therapeutics ApS manufactures pharmaceutical preparations. The company is based in Copenhagen, Denmark. The CEOs are Søren Sylvester Skjærbæk, Thomas Kirkegaard Jensen. The Danish company was founded in 2022. | Health Technology |
- Bolsa de valores
- Insiders
- Camilla Hansen